Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promotes the survival of insulin-producing beta cells and reverses diabetes in mouse models 1 . To translate these findings into humans, we conducted a randomized double-blind placebo-controlled phase 2 clinical trial (NCT02372253) to assess the efficacy and safety of oral verapamil added for 12 months to a standard insulin regimen in adult subjects with recent-onset T1D. Verapamil treatment, compared with placebo was well tolerated and associated with an improved mixed-meal-stimulated C-peptide area under the curve, a measure of endogenous beta cell function, at 3 and 12 months (prespecified primary endpoint), as well as with a lower increase in insulin requirements, fewer hypoglycemic events and on-target glycemic control (secondary endpoints). Thus, addition of once-daily oral verapamil may be a safe and effective novel approach to promote endogenous beta cell function and reduce insulin requirements and hypoglycemic episodes in adult individuals with recent-onset T1D.
Pancreatic beta cell loss is a key factor in the pathogenesis of type 1 diabetes (T1D), but therapies to halt this process are lacking. We previously reported that the approved antihypertensive calcium-channel blocker verapamil, by decreasing the expression of thioredoxin-interacting protein, promotes the survival of insulin-producing beta cells and reverses diabetes in mouse models 1 . To translate these findings into humans, we conducted a randomized double-blind placebo-controlled phase 2 clinical trial (NCT02372253) to assess the efficacy and safety of oral verapamil added for 12 months to a standard insulin regimen in adult subjects with recent-onset T1D. Verapamil treatment, compared with placebo was well tolerated and associated with an improved mixed-meal-stimulated C-peptide area under the curve, a measure of endogenous beta cell function, at 3 and 12 months (prespecified primary endpoint), as well as with a lower increase in insulin requirements, fewer hypoglycemic events and on-target glycemic control (secondary endpoints). Thus, addition of once-daily oral verapamil may be a safe and effective novel approach to promote endogenous beta cell function and reduce insulin requirements and hypoglycemic episodes in adult individuals with recent-onset T1D.
T1D is characterized by a gradual destruction and loss of insulin-producing pancreatic beta cells, thus resulting in a lifelong dependence on exogenous insulin to maintain normoglycemia. In addition, T1D is associated with a risk of secondary complications, including cardiovascular disease, kidney failure, blindness and amputations. Although it is often diagnosed in children and young adults, T1D can occur at any age and, in contrast to what was previously thought, many patients retain a small number of functioning beta cells even years after diagnosis 2, 3 . Moreover, large studies such as the Diabetes Control and Complications Trial have shown that even a small amount of preserved endogenous insulin production has major beneficial effects in terms of outcome, overall glycemic control and prevention of complications 4 . Although major advances have been made in terms of sophisticated insulin preparations as well as insulin-delivery and glucose-monitoring systems, there is still no effective therapeutic approach available that targets beta cell loss in diabetes. Attempts to replace beta cells by pancreas or islet transplantation are unfortunately associated with potentially severe side effects due to the necessary immunosuppression. In addition, recent stem-cell-derived approaches are still in their infancy, thus underlining the urgent need for an effective pharmacological approach to promote the patient's own insulin-producing beta cell mass.
In this regard, we discovered thioredoxin-interacting protein (TXNIP), a cellular redox regulator, as an attractive therapeutic target. We originally identified TXNIP as the top glucose-induced gene in a human-islet microarray study and found that beta cell expression of TXNIP is elevated in diabetes [5] [6] [7] . Moreover, TXNIP overexpression induces beta cell apoptosis, whereas TXNIP deficiency promotes endogenous beta cell survival and prevents diabetes in different mouse models 6, 8, 9 . We further discovered that the approved antihypertensive drug and calcium-channel blocker verapamil effectively lowers beta cell TXNIP expression in rodent beta cells and islets as well as in human islets 1 . This effect is based on the established mode of action of verapamil, i.e., blockade of L-type calcium channels and the resulting decrease in intracellular free calcium leading to inhibition of TXNIP transcription 1 . Tissues with high expression of L-type calcium channels, such as beta cells and the heart, are therefore most likely to benefit from the resulting TXNIP inhibition. Indeed, verapamil and TXNIP downregulation have been shown to have beneficial effects in the diabetic heart [10] [11] [12] , thus making adverse effects in this regard unlikely.
Moreover, in mouse models of diabetes, oral administration of verapamil promotes functional beta cell mass and prevents and even reverses overt diabetes 1 . In addition, we found that downregulating TXNIP also improves beta cell function including insulin production 13 and secretion 14 , effects that may help increase the amount of insulin synthesized and secreted per beta cell, especially in the context of the dramatically decreased beta cell mass occurring in T1D. Finally, TXNIP has been shown to be involved in inflammasome activation 15 , thus suggesting that its downregulation might also have some anti-inflammatory effects.
Verapamil has been approved by the US Food and Drug Administration and has been widely used as an antihypertensive for more than 30 years. Although several retrospective studies have emerged suggesting that verapamil use might be associated with a lower risk of developing type 2 diabetes [16] [17] [18] , no prospective interventional trial had been performed to determine whether our preclinical findings might be translatable to humans and whether verapamil might be able to enhance functional beta cell mass and have beneficial effects in patients with T1D. We therefore conducted a randomized double-blind placebo-controlled pilot-andfeasibility trial to assess the efficacy and safety of oral verapamil added for 12 months to a standard insulin therapy in adult subjects with recent-onset T1D.
A total of 32 subjects who were 18-44 years of age and were diagnosed with T1D within the previous 3 months were screened with mixed-meal tolerance tests (MMTT) for the presence of a minimal stimulated C-peptide value of ≥ 0.2 nmol/L and at least one positive T1D-associated autoantibody ( Fig. 1 ). Among this group, 26 subjects qualified and underwent randomization to receive oral
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Fernando Ovalle 1 , Tiffany Grimes 1 , Guanlan Xu 1 , Anish J. Patel 1 , Truman B. Grayson 1 , Lance A. Thielen 1 , Peng Li 2 and Anath Shalev 1 * Letters NaTure MeDiCiNe verapamil or placebo in addition to their insulin therapy. Two subjects (8%) who had been randomized to the verapamil group had to be excluded before the collection of any outcome information (one relapsed into drug abuse, and one refused to take scheduled insulin), thus resulting in a verapamil group of 11 subjects and a placebo group of 13 subjects who completed the 1-year trial. The baseline characteristics were well balanced between the two treatment groups, and none of the characteristics showed any significant differences ( Supplementary Table 1 ). In addition, the average HbA1c was very similar in the verapamil and the placebo groups (6.6 and 6.8 percent, respectively).
To assess endogenous beta cell function, our primary endpoint, we measured the MMTT-stimulated C-peptide area under the curve (AUC) at baseline, 3 months and 12 months. Indeed, repeatedmeasures analysis of variance (ANOVA) suggested a significant difference among the group/time means. Two-sided Student's t test showed that there was no significant difference at the 0-month baseline (P = 0.300), and the stimulated C-peptide AUC was significantly larger in the verapamil group than the placebo group at both 3 months (P = 0.0270) and 12 months (P = 0.0186; Fig. 2a ). We also used an analysis of covariance (ANCOVA) model, adjusting for baseline to correct for any preexisting differences at 0 months, and the results still revealed that the stimulated C-peptide AUC was significantly larger in the verapamil group than the placebo group at both 3 and 12 months (P = 0.0334 and P = 0.0377, respectively). In addition, we assessed the change from baseline at 3 and 12 months in each individual, and the results revealed again that subjects on verapamil maintained a significantly higher percentage of their stimulated C-peptide AUC, as compared with subjects on placebo (P = 0.0491 and P = 0.0451, respectively; Fig. 2b ). Moreover, we also used a multiple-imputation approach to impute the missing values for the two subjects that had to be excluded, reanalyzed the outcomes with the imputed data and conducted a sensitivity analysis. Notably, the results from the sensitivity analysis were consistent with the results presented above ( Supplementary Table 2 ).
To assess changes in exogenous insulin requirements, one of the secondary endpoints, we also analyzed the total daily dose of insulin (TDDI) required to maintain glycemic control. At baseline, the insulin requirements were 0.26 units/kg/d for both the verapamil and placebo groups. However, by 12 months, the TDDI increased 70% in the placebo group, a result consistent with disease progression, whereas the increase was only 27% in the verapamil group, thus indicating a significant treatment difference of -43%, 95% CI, -84 to -1 (P = 0.0312; Fig. 3a ). Notably, both groups maintained excellent glycemic control throughout the trial, as demonstrated by an average HbA1c measurement between 6 and 7 percent ( Fig. 3b ). At 6 months, there was a nonsignificant trend toward a lower HbA1c in the verapamil group (P = 0.083). Moreover, the average rate of hypoglycemic events, defined as blood glucose episodes of ≤ 2.2 mmol/L per month, was 0.5 events per month in the verapamil group and 2.7 events per month in the placebo group (treatment difference -2.2 events per month, 95% CI, -4.2 to -0.1, P = 0.0387; Fig. 3c ). In addition, although the effect was not significant, verapamil-treated subjects spent more time within the target range of 3.9-10 mmol/L blood glucose (82% versus 72%, P = 0.130) and less time in the hyperglycemic (> 10 mmol/L) or hypoglycemic (< 3.9 mmol/L) range, as compared with the placebo group and assessed through continuous glucose monitoring system (CGMS) data ( Fig. 3d ). Notably, verapamil treatment did not affect fasting serum glucagon levels (20.5 ng/L in the verapamil group versus 20.9 ng/L in the placebo group; P = 0.938). Together, these findings 32 subjects with recent-onset T1D were screened for autoantibodies and MMTT-stimulated C-peptide Five were not eligible Three were antibody negative Two were C-peptide negative One declined 26 subjects were randomized to receive oral verapamil or placebo in a double-blind fashion 11 subjects completed 1 year of verapamil 13 subjects completed 1 year of placebo Two were excluded One relapsed into iv drug abuse One refused scheduled insulin 
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We also found that the overall adverse events were very mild, and none required treatment discontinuation or dose interruption or reduction (Supplementary Table 3 ). The only adverse event that occurred with higher incidence in the verapamil group was constipation, the most common side effect of verapamil. However, the reported symptoms were mild and did not require any medical intervention. In addition, there were no severe hypoglycemic episodes requiring the assistance of another person, as defined by the American Diabetes Association, in either treatment group. Importantly, verapamil did not cause any hypotension even in these normotensive subjects, and monitoring of the participants' systolic and diastolic blood pressure throughout the study did not reveal any trend toward lower levels in the verapamil group ( Fig. 4a,b ). Moreover, all subjects maintained a normal heart rate (Fig. 4c ), and electrocardiogram (EKG) analysis revealed that verapamil treatment did not cause any alterations in the QT or PR interval (Fig. 4d,e ).
This randomized double-blind placebo-controlled phase 2 trial is, to our knowledge, the first prospective study demonstrating that oral verapamil added to standard insulin therapy promotes endogenous beta cell function and lowers exogenous insulin requirements and hypoglycemic episodes in patients with recent-onset adult T1D.
Overall, verapamil was very well tolerated, and aside from mild constipation, no clinically significant adverse events were reported, in agreement with its proven safety profile. Notably, no hypotension and no EKG changes were observed, thus demonstrating that verapamil can also be used safely in younger, normotensive subjects with T1D.
The finding that verapamil is effective in promoting endogenous beta cell function, as assessed with the validated method of MMTTstimulated C-peptide AUC in individuals with T1D, is consistent with the results of our preclinical studies in isolated human islets and mouse models of diabetes, in which verapamil has been shown to reduce the detrimental expression of TXNIP, prevent beta cell apoptosis, promote beta cell mass and improve glucose homeostasis 1 . However, we cannot rule out the possibility that verapamil might also improve insulin sensitivity. In fact, improved insulin sensitivity might lead to overall better blood glucose control and account for the other associated secondary outcomes including decreased exogenous insulin requirements, which in turn might decrease the number of hypoglycemic episodes. In type 2 diabetes, verapamil has also been suggested to possibly inhibit gluconeogenesis 19 . Although there is no indication that this inhibition occurred in our study participants, and their glucagon levels remained unchanged, we cannot exclude the possibility that such an effect might have contributed to the observed beneficial effects of verapamil on blood glucose.
Our results and the notion of verapamil having beneficial effects in the context of diabetes are further supported by retrospective studies focusing on type 2 diabetes. These include a recent study using Taiwan's National Health Insurance Research Database, in which 
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verapamil use was associated with a lower incidence of newly diagnosed type 2 diabetes 16 , as well as previous International Verapamil SR/Trandolapril (INVEST) spin-off studies, which also found that participants in the verapamil arm had a lower risk of developing diabetes 17, 18 . In addition, in an association study using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, we found that diabetic verapamil users had fasting blood glucose levels as much as 2.1 mmol/L lower than those of subjects with diabetes who were not taking calcium-channel blockers 20 .
Interventional trials on T1D have primarily focused on suppressing or modulating the immune response [21] [22] [23] [24] [25] ; however, it has now become apparent that to achieve sustained improvement, effective approaches to promote functional beta cell mass must be applied simultaneously 24, 26 . Our findings suggest that verapamil may represent such a novel and rational approach to enhance endogenous beta cell function. In addition, verapamil treatment was well tolerated, was not associated with any clinically significant adverse events and seemed to be effective even when added by itself to a standard insulin regimen. In future studies, however, it will also be interesting to test verapamil in combination with immunomodulatory interventions.
The main limitation of this pilot-and-feasibility trial is the relatively small number of subjects included, and our findings will need to be confirmed in future larger trials with longer follow-up. In addition, because no in vivo measures are available to assess islet TXNIP levels in humans, whether verapamil functioned in the study participants as it did in the prior rodent studies remains unclear. However, our study sample appears to be representative of the T1D population, because the absolute numbers of C-peptide AUC at baseline and over time were comparable to those observed in large T1D trials 27, 28 . In addition, our trial was randomized, double-blind and placebo controlled, and the study groups were well balanced in terms of their baseline characteristics, glycemic control and insulin requirements. In addition, although we monitored participants for a full year rather than focusing just on the first few months, future longer-term studies are needed to determine whether the beneficial effects can be sustained with (or without) continuous verapamil treatment. Mining the electronic-health-record data for any epidemiological evidence that verapamil might improve diabetes control in people with T1D should also be interesting. Finally, given these promising results in adults with T1D, the safety and efficacy of oral verapamil will also need to be tested in a pediatric T1D population. Because the natural course of T1D can be quite different and is often more aggressive in children, the results of the current study may not necessarily translate into pediatric individuals, and first confirming that verapamil also has beneficial effects in this unique population is particularly important.
In conclusion, once-daily oral verapamil added to a standard insulin regimen may provide a safe and effective novel approach to promote and preserve an individual's own beta cell function, delay beta cell loss and disease progression for at least 1 year and reduce insulin requirements and hypoglycemic episodes in adults with recent-onset T1D.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0089-4.
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Methods Study design and participants. The trial protocol was approved by the Institutional Review Board of the University of Alabama at Birmingham (UAB) and complied with all ethical regulations. All patients provided written informed consent. The trial was also officially registered with ClinicalTrials.gov (NCT02372253). The trial was designed as a double-blind placebo-controlled study. Participants were randomized in a 1:1 ratio, through a simple randomization approach using computer-generated random numbers, to receive oral verapamil or matching placebo in addition to standard care with continuous subcutaneous insulin infusion via an insulin pump. No other diabetes medications were permitted during the study. The prespecified primary endpoint was endogenous beta cell function, as determined by measurement of stimulated C-peptide during a 2-h MMTT, as previously validated 27, 29, 30 . Secondary endpoints included changes in exogenous insulin requirements, as assessed through TDDI, and overall glycemic control, as assessed through HbA1c, hypoglycemic events and use of a CGMS. This pilot study was not powered to detect differences in these secondary endpoints. In addition, because improved blood glucose control could potentially affect all of them, these secondary outcomes are likely to be linked and may not represent separate issues.
Eligible participants were 18-45 years of age and had been diagnosed with T1D within the previous 3 months. The individual diagnostic factors are listed in Supplementary Table 4 . In addition, subjects were required to have a body mass index < 30; to show positive autoantibodies to at least one of the antigens GAD65, IA-2, ICA, MIAA or ZnT8; and to reach a minimal stimulated C-peptide value of ≥ 0.2 nmol/L during the screening MMTT. Furthermore, participants were required to agree to intensive management of their diabetes with an HbA1c goal of < 7.0% and to wear an insulin pump and CGMS. Individuals with concomitant use of glucagon-like peptide-1 receptor agonists or oral antidiabetic agents, or with any other serious disease were excluded. Other non-diabetes-related medications included levothyroxine (one subject), losartan (one subject), sertraline (one subject) and atorvastatin plus doxepin plus topiramate (one subject).
Participants were randomly assigned to receive a once-daily oral dose of sustained-release verapamil (titrated over the first 3 months from 120 mg to 360 mg) or placebo for a total of 12 months in addition to their insulin therapy. (This dose was chosen according to its demonstrated tolerability and effectiveness in terms of calcium-channel blockade and considering that the maximal recommended daily dose for verapamil is 480 mg.) Participants were seen monthly during the first three months and then every 3 months until the end of the study, and were carefully monitored for any occurrence of hypotension, bradycardia or EKG changes (PR-or QT-interval prolongation).
Randomization and masking.
For masking, verapamil (120 mg sustained release) and placebo were overencapsulated, thus resulting in identically looking capsules and packaging, and were assigned different 'lot numbers' . The trial team and investigators had no access to the lot-number code throughout the study. Participants were assigned to lot numbers on a continuous basis via a web-based computer-generated random-number sequence. Titration of the treatment was achieved by increasing the number of capsules. Participants, care providers and investigators assessing the outcomes remained blinded until completion of the data analysis.
Procedures. Endogenous beta cell function was assessed at baseline, 3 months and 12 months on the basis of stimulated C-peptide AUC during an MMTT, as described previously 27, 29 . The MMTT was performed only when fasting blood glucose levels were within the range of 3.9-11.1 mmol/L; otherwise, the test was rescheduled. Blood samples were collected at -10, 0, 15, 30, 60, 90 and 120 min for serum C-peptide analysis. The C-peptide AUC (0-120 min) was calculated by using the trapezoidal rule and was divided by the time of the test to obtain the mean AUC (in nmol/L) 29 . Furthermore, to assess the effects on exogenous insulin requirements, the change in TDDI from baseline was calculated by analysis of each subject's mean daily insulin use during the 2 weeks preceding the 3-, 6-, 9-and 12-month clinic visits. Glycemic control was monitored by measurement of HbA1c every 3 months as well as the number of hypoglycemic episodes and the percentage time spent within the target range of 3.9-10 mmol/L, or above or below it, as calculated from CGMS data. The main safety parameters included measurements of blood pressure, heart rate, PR and QT intervals by EKG, and blood chemistry, including liver-function tests.
Statistical analysis. Participants' demographic characteristics and outcomes were summarized as mean and standard errors for continuous variables, and frequency and proportion for categorical variables. The group comparison of baseline measures was conducted with chi-square test, Fisher's exact test or Student's t test where appropriate. The normal distribution assumption was checked with Q-Q plots. All tests were two sided. For the primary and secondary outcomes, a repeated-measures two-way ANOVA was conducted first; then, where appropriate, the ANCOVA model controlling for the baseline was conducted to compare group means at the 3-or 12-month time points. Sample-size estimates were based on the primary outcome of endogenous beta cell function, according to stimulated C-peptide AUC; on previously reported sample-size considerations for studying treatment effects on beta cell function at 12 months in newly diagnosed patients with T1D who were older than 18 years in the T1D Trial Network 31 ; and on recommendations for planning pilot studies in clinical and translational research 32 . Statistical analyses were performed in SAS 9.4. Sensitivity analysis was conducted with a multiple-imputation approach, as described previously 33 .
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. references 29. Greenbaum 
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